<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586166</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00068839</org_study_id>
    <nct_id>NCT04586166</nct_id>
  </id_info>
  <brief_title>Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally Invasive Sacrocolpopexy</brief_title>
  <acronym>SASS</acronym>
  <official_title>SASS: Randomized Trial of Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for Concomitant Management of Stress Urinary Incontinence During Minimally Invasive Sacrocolpopexy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      SASS (Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI During Minimally&#xD;
      Invasive Sacrocolpopexy) will be a multicenter, prospective, randomized, single-blind&#xD;
      non-inferiority trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SASS aims to compare the efficacy of a single-incision (SIS) versus a retropubic mid-urethral&#xD;
      sling (RP) placed at the time of minimally invasive sacrocolpopexy in women with pelvic organ&#xD;
      prolapse and objectively confirmed stress urinary incontinence (SUI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be masked during the five-year follow-up period. Precautions will be taken to minimize unmasking the study groups. Since RP (retropubic) slings require two suprapubic stab incisions, identical sham incision will also be performed in the SIS (Single-Incision Sling) group.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with subjectively bothersome stress incontinence</measure>
    <time_frame>6 weeks after surgery</time_frame>
    <description>Measured by a positive response of &gt; 1 to Question 17 on Pelvic Floor Distress Inventory short form-20 (PFDI-20). Response scale from 0 to 4. Symptoms Not Present = NO 0 = not present Symptoms Present = YES, scale of bother: 1 = not at all, 2 = somewhat, 3 = moderately, 4 = quite a bit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with subjectively bothersome stress incontinence</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Measured by a positive response of &gt; 1 to Question 17 on Pelvic Floor Distress Inventory short form-20 (PFDI-20). Response scale from 0 to 4. Symptoms Not Present = NO 0 = not present Symptoms Present = YES, scale of bother: 1 = not at all, 2 = somewhat, 3 = moderately, 4 = quite a bit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with subjectively bothersome stress incontinence</measure>
    <time_frame>3 years after surgery</time_frame>
    <description>Measured by a positive response of &gt; 1 to Question 17 on Pelvic Floor Distress Inventory short form-20 (PFDI-20). Response scale from 0 to 4. Symptoms Not Present = NO 0 = not present Symptoms Present = YES, scale of bother: 1 = not at all, 2 = somewhat, 3 = moderately, 4 = quite a bit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with subjectively bothersome stress incontinence</measure>
    <time_frame>5 years after surgery</time_frame>
    <description>Measured by a positive response of &gt; 1 to Question 17 on Pelvic Floor Distress Inventory short form-20 (PFDI-20). Response scale from 0 to 4. Symptoms Not Present = NO 0 = not present Symptoms Present = YES, scale of bother: 1 = not at all, 2 = somewhat, 3 = moderately, 4 = quite a bit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VAS (Visual Analogue Scale Surgeon ease of Use)</measure>
    <time_frame>Baseline, Surgery, Post Op: week 2, week 6, year 1, year 2, year 3, and year 5</time_frame>
    <description>This will be assessed using the numeric rating scale (NRS). The score is 0-10, with higher scores denoting a greater degree of satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Organ Prolapse/Urinary Incontinence Sexual Functioning Short Form (PISQ-IR)</measure>
    <time_frame>Baseline, Surgery, Post Op: week 2, week 6, year 1, year 2, year 3, and year 5</time_frame>
    <description>Questionnaire consists of 20 questions regarding sexual functioning. PISQ-IR consists of two parts. Part 1, for not Sexually Active (NSA) women, and par 2 for SA women. Response value varies from 1 to 5. Part 1, for not SA (NSA) women, where higher scores indicate a greater impact of the condition on sexual inactivity. Part 2, for SA women, with higher scores indicating better sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Impact (PFIQ-SF7)</measure>
    <time_frame>Baseline, Surgery, Post Op: week 2, week 6, year 1, year 2, year 3, and year 5</time_frame>
    <description>Consists of 3 scales with each 7 questions and will be used to assess quality of life regarding pelvic floor related quality of life. The total score is the sum of the three scale score with a range of 0-300. Higher values indicate a greater degree of bother</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I)</measure>
    <time_frame>Baseline, Surgery, Post Op: week 2, week 6, year 1, year 2, year 3, and year 5</time_frame>
    <description>7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative baseline - lower scores denote improvement - 1= Very much better to 7 = Very much worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of post-void residual (PVR) volume</measure>
    <time_frame>Baseline, Surgery, Post Op: week 2, week 6, year 1, year 2, year 3, and year 5</time_frame>
    <description>Post Void Residual/PVR measurement - (collected via bladder scan or CIC) (Clean Intermittent Catheterization). PVR can be as minimum as 0ml of an average bladder capacity of 400ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants needing Retreatment</measure>
    <time_frame>6 month up to 5 year post-surgery</time_frame>
    <description>Surgical intervention for urinary retention (sling lysis) at any time point after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants needing bladder drainage</measure>
    <time_frame>beyond 6 weeks post-surgery</time_frame>
    <description>Requirement of urinary catheter due to incontinence or retention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic Floor Distress Inventory (PFDI-SF20)</measure>
    <time_frame>Baseline, Surgery, Post Op: week 2, week 6, year 1, year 2, year 3, and year 5</time_frame>
    <description>The PFDI-20 has a total of 20 questions and 3 scales (Urinary Distress Inventory, Pelvic Organ Prolapse Distress Inventory, and Colorectal-Anal Distress Inventory). The outcomes of this questionnaire will be evaluated stratified by compartment. Each item produces a response of 0 to 4, the average response in each scale is multiplied by 25 to obtain the scale score (range 0 to 100). The total score is the sum of the three scale score with a range of 0-300. Higher values indicate a greater degree of bother.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <condition>Pelvic Floor Disorders</condition>
  <arm_group>
    <arm_group_label>RP Sling Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SIS Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RP Sling</intervention_name>
    <description>Participants assigned to the retropubic (RP) sling group will have the RP sling placement procedure.</description>
    <arm_group_label>RP Sling Group</arm_group_label>
    <other_name>Advantage RP Sling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SIS</intervention_name>
    <description>Participants assigned to the single-incision sling (SIS) group will have the SIS placement procedure.</description>
    <arm_group_label>SIS Group</arm_group_label>
    <other_name>Solyx SIS System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 21 years of age&#xD;
&#xD;
          -  Vaginal bulge symptoms as indicated by an affirmative response of &gt;1 to question 3 of&#xD;
             the PFDI-SF20&#xD;
&#xD;
          -  POP â‰¥ stage II according to the pelvic organ prolapse quantification (POP-Q) system45,&#xD;
             with evidence of apical descent&#xD;
&#xD;
          -  Women being considered for minimally invasive sacrocolpopexy (with or without&#xD;
             concomitant hysterectomy)&#xD;
&#xD;
          -  Objective SUI: positive standardized cough stress test on clinical examination or on&#xD;
             urodynamic study with reduced prolapse&#xD;
&#xD;
          -  Understanding and acceptance of the need to return for all scheduled follow-up visits&#xD;
             and willing to complete study questionnaires&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior surgery for stress urinary incontinence including mid-urethral sling; Burch/MMK;&#xD;
             fascial pubovaginal sling (autologous, xenograft or allograft); and urethral bulking&#xD;
             injection&#xD;
&#xD;
          -  Any serious disease, or chronic condition, that could interfere with the study&#xD;
             compliance&#xD;
&#xD;
          -  Unwilling to have a synthetic sling&#xD;
&#xD;
          -  Untreated and unresolved urinary tract infection&#xD;
&#xD;
          -  Poorly-controlled diabetes mellitus (HgbA1c &gt; 9 within 3 months of surgery date)&#xD;
&#xD;
          -  Neurogenic bladder/ pre-operative self-catheterization&#xD;
&#xD;
          -  Elevated post-void residual/PVR (&gt;150 ml) that does not resolve with prolapse&#xD;
             reduction testing (pessary, prolapse reduced uroflow or micturition study)&#xD;
&#xD;
          -  Prior pelvic radiation&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Current genitourinary fistula or urethral diverticulum&#xD;
&#xD;
          -  Planned concomitant bowel related surgery including sphincteroplasty and perineal&#xD;
             rectal prolapse surgery, rectovaginal fistula repair, hemorrhoidectomy&#xD;
&#xD;
          -  Pregnant or Planning to Conceive&#xD;
&#xD;
          -  Incarcerated&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients with pelvic organ prolapse.</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine A Matthews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sachin N Vyas, MS,PhD</last_name>
    <phone>336-713-4098</phone>
    <email>svyas@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine A Matthews, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Florida Robotic and Minimally Invasive Urogynecology</name>
      <address>
        <city>Coconut Creek</city>
        <state>Florida</state>
        <zip>33073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Brocki</last_name>
      <phone>954-570-7644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Miller, LPN, CCRC</last_name>
      <phone>706-721-9680</phone>
      <email>jmiller7@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara R Henley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pooja Sharma, BS, BA, BMS</last_name>
      <phone>312-926-7846</phone>
      <email>pooja.sharma@nm.org</email>
    </contact>
    <investigator>
      <last_name>Kimberly Kenton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Urogynecology Associates</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter L Rosenblatt</last_name>
      <phone>617-354-5452</phone>
    </contact>
    <investigator>
      <last_name>Peter L Rosenblatt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sachin N Vyas, MS,PhD</last_name>
      <phone>336-713-4098</phone>
    </contact>
    <investigator>
      <last_name>Catherine A Matthews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pelvic Floor Foundation of South Africa, University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <zip>8001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle De Koker</last_name>
      <phone>27-64-650-6199</phone>
      <email>christelle.dekoker@uct.ac.za</email>
    </contact>
    <investigator>
      <last_name>Stephen Jeffery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 7, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retropubic Sling</keyword>
  <keyword>Single-Incision Sling</keyword>
  <keyword>Sacrocolpopexy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
    <mesh_term>Pelvic Floor Disorders</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imidacloprid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only limited dataset without PHI will be shared with the study bio statistical group.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

